Harmon Cyrus 4
4 · Olema Pharmaceuticals, Inc. · Filed Jun 4, 2024
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2024-06-03$10.93/sh−5,000$54,650→ 786,283 total - Sale
Common Stock
2024-06-04$12.33/sh−5,000$61,650→ 781,283 total - Sale
Common Stock
2024-05-31$9.41/sh−15,000$141,150→ 791,283 total
Holdings
- 122,028(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
- [F2]The weighted average sale price for the transaction reported was $9.41, and the range of prices was between $9.34 and $9.56. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $10.93, and the range of prices was between $10.91 and $11.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $12.33, and the range of prices was between $12.23 and $12.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.